NeuroQ 3.8
NeuroQ 3.8 is a medical device (FDA Class II; FDA product code KPS, System, Tomography, Computed, Emission) made by Syntermed Incorporated, cleared under FDA 510(k) K130451 on 17 May 2013 and listed in FDA GUDID since 12 Nov 2020 (UDI-DI B133NEUROQ300), active as of 23 Oct 2026.
Active
510(k)
Valid until
No expiry
FDA recalls
None found
Documents
Trust
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | GUDID listing | NumberB133NEUROQ300 | Date12 Nov 2020 | StatusListed |
| United States | FDA 510(k)SESE | NumberK130451 | Date17 May 2013 | StatusActive |
Official records
- FDA 510(k) database K130451
From the FDA record
- Device description
- NeuroQ™ has been developed to aid in the assessment of human brain scans through quantification of mean pixel values lying within standardized regions of interest, and to provide quantified comparisons with brain scans derived from FDG-PET studies of defined groups having no identified neuropsychiatric disease or symptoms, i.e., asymptomatic controls (AC). The Program provides automated analysis of brain PET scans, with output that includes quantification of relative activity in 240 different brain regions, as well as measures of the magnitude and statistical significance with which activity in each region differs from mean activity values of brain regions in the AC database. The program can be used to compare activity in brain regions of individual scans between two studies from the same patient, between symmetric regions of interest within the brain PET study, and to perform an image fusion of the patients PET and CT data. The program can also be used to for assisting in the assessment of prognosis in patients undergoing dementia evaluation with respect to the likelihood of progression of symptomatic disease, to provide analysis of amyloid uptake levels in the brain, and to evaluate and to provide a quantitative analysis of uptake levels in basal ganglia structures of the brain. The program processes the studies automatically, however, user verification of output is required and manual processing capability is provided.
- MRI safety
- Labeling does not contain MRI Safety Information
- Natural rubber latex
- No latex statement on the label
- Sterility
- Supplied non-sterile
Across registries
- FDA 510(k) K130451 decided 17 May 2013 Active
- FDA GUDID UDI-DI B133NEUROQ300 listed 12 Nov 2020 Listed
Timeline
- Cleared FDA 510(k) K130451
- Listed FDA GUDID B133NEUROQ300
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- Trade name
- NeuroQ
- Generic name
- Multidisciplinary medical image management software
- Model / reference
- 3.8
- Primary DI / UDI-DI
- B133NEUROQ300
- 510(k) Number
- FDA product code
- KPS
- GMDN term
- Multidisciplinary medical image management software
- Device class
- Class II
- Regulation number
- 892.1200
- GUDID distribution status
- In Commercial Distribution
Similar devices
Other devices filed under FDA product code KPS (System, Tomography, Computed, Emission).
- CARDIUS-1, CARDIUS-2, CARDIUS-3, 2020TC SPECT IMAGING SYSTEM by Digirad Corp.
- CARDIUS-1, -2, -3, AND CARDIUS 1, 2, 3 XPO SPECT IMAGING SYSTEMS, 2020TC SPECT IMAGING SYSTEM by Digirad Corp.
- WBR XPRESS.CARDIAC, WBR XPRESS.BONE; WBR XACT.CARDIAC, WBR XACT.BONE by Ultraspect, Ltd.
- GEMINI GXL by Philips Medical Systems (Cleveland), Inc.
- STEP OPTION TO PRISM 2000 by Philips Medical Systems (Cleveland), Inc.
- MULTICAM 3000 ECO by Inter Medical Medizintechnik GmbH
- BRIVO NM 615 by GE Healthcare
- POSICAM TM(MODEL 3.2, 4.3, 6.5) by Position Corp.
- AUTOQUANT PLUS by Adac Laboratories
- Biograph Horizon by SIEMENS MEDICAL SOLUTIONS USA, INC.